What's the Latest on Iron Therapy?

Authors

  • Andrea Cavalli S.C. Nefrologia e Dialisi, Ospedale “Alessandro Manzoni”, Lecco
  • Giuseppe Pontoriero S.C. Nefrologia e Dialisi, Ospedale “Alessandro Manzoni”, Lecco

DOI:

https://doi.org/10.33393/gcnd.2014.924

Keywords:

Iron therapy, Endovenous iron, DOPPS, Mortality, Adverse events

Abstract

Anemia is a common complication of chronic kidney disease (CKD) and is usually treated with erythropoiesis-stimulating agents (ESA) and iron supplementation. Endovenous iron therapy has been recently ruled (and limited) by both the European and Italian medicines agencies due to serious, despite rare, adverse events. A recent analysis of data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) has shown an association between high endovenous iron therapy (more than 300 mg/month) and increased mortality in patients with hemoglobin levels higher than 10 g/dL. The new molecules available on the market should have a better safety profile and several advantages related to the possibility of administering a high iron dose in a single infusion. Iron supplementation through the dialysate and through new phosphate binders demonstrates the great scientific interest in this important field, also to the advantage of our CKD patients.

Downloads

Download data is not yet available.

Published

2014-02-10

How to Cite

Cavalli, A., & Pontoriero, G. (2014). What’s the Latest on Iron Therapy?. Giornale Di Clinica Nefrologica E Dialisi, 26(3), 296–300. https://doi.org/10.33393/gcnd.2014.924

Issue

Section

Short Communications

Metrics